EUPATI hit an important milestone this August, celebrating 4 years since it became an independent non-profit Foundation in the Netherlands.
Before, EUPATI was hosted under IMI and later, EPF, from 2017 until 2020. EUPATI’s mission is to provide accessible, innovative and inclusive education that empowers patients and patient representatives to create a more efficient healthcare system. Today, EUPATI has a growing network of stakeholders and trained experts. With this expanding level of engagement, we strive to make patient advocacy a requirement at a global level in the years to come!
Read their celebration release:
”🎉 Celebrating 4 Years of EUPATI as an Independent Foundation! 🎉
Yesterday marked a special milestone for EUPATI! It has been 4 years since we established ourselves as an independent foundation, and what an incredible journey it’s been! 🚀
Since our launch on 01 February 2012, funded by the Innovative Medicines Initiative (IMI) and later hosted by the European Patients’ Forum (EPF), we’ve grown, learned, and collaborated with amazing individuals and organisations. We’ve been dedicated to empowering patients in medicines R&D and refining our values and principles along the way.
🌟 Today, we stand proud with:
50 Partner Organisations
24 EUPATI National Platforms
Over 330 EUPATI Fellows
Over 250 Trained National Patient Experts
Over 1170 Trained Professionals from Industry and Academia
And more than 7.3 Million Users on EUPATI Toolbox!
These numbers are a testament to the power of patient involvement through education and information, and this need to drive positive change in our global health systems.
A huge thank you to our entire EUPATI network for your continuous work and support – together, we are stronger! Here’s to many more successful years ahead! 🙌”
Discover more about EUPATI:
EUPATI is a successful multi-stakeholder organisation that provides education and training for patient, patient representatives, industry and academia. The aim is to increase the capacity and capability of patients and patient representatives to understand and meaningfully contribute to medicines research and development (R&D), and to improve the availability of medical information for patients and other stakeholders.
